Navigation Links
Sigma-Aldrich Accelerates Analytical Research and Extends Benefits of Fused-Core Particle Technology to All HPLC Users with the Launch of New Ascentis Express 5 Micron Particle by Supelco
Date:7/25/2012

ST. LOUIS, July 25, 2012 /PRNewswire/ -- Sigma-Aldrich® Corporation (NASDAQ: SIAL) announced today its Supelco® brand launched the Ascentis® Express C18, 5 micron particle size column to improve speed and increase efficiencies in high purity liquid chomatography (HPLC) procedures. The new columns are based on innovative Fused-Core® particle technology, which enables the production of columns capable of achieving greater speed and efficiencies than conventional 5 micron particle columns. The Ascentis Express family provides scientists a premier choice for performance improvement on traditional HPLC systems and eliminates the concerns associated with smaller particle columns.

(Logo: http://photos.prnewswire.com/prnh/20050215/CGSIGMAALLOGO)

The new columns deliver the speed and resolving power of conventional 3 micron particle columns, as well as provide greater ruggedness and a longer life cycle than columns using sub 2 micron particles. Operating back pressures of the new column family are comparable to columns using 5 micron particles, ensuring pressure limits are not exceeded in conventional HPLC instrumentation. The Ascentis Express line is scalable from ultra high purity liquid chromatography (UHPLC) to legacy HPLC systems.

"Supelco's latest extension to the Ascentis Express line allows scientists to boost the performance of legacy HPLC systems and effortlessly transfer methods amongst sites or contract research organizations (CRO) without incompatibility concerns," said Dr. Wayne Way, HPLC/GC Market Segment Manager, Supelco. "These columns are expected to be extremely beneficial for bioanalytical LC/MS as they excel at the high flow rates and high throughput demands of these methods.  Furthermore, the large parti
'/>"/>

SOURCE Sigma-Aldrich Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
2. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
3. Army Researcher Develops Potential Vaccine Carrier That May Give Stockpiling Efforts A Shot In The Arm
4. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
5. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
6. Southern Research Signs Agreement with Apath, LLC to Conduct Preclinical Studies with Virus-Based HCV Screenings
7. Galenea to Receive $6 Million From The Stanley Medical Research Institute to Progress Pro-Cognitive Drug Discovery and Development Program
8. Upsher-Smith Research Shows Unique Pharmacokinetic Profile of USL255 Extended Release Topiramate
9. Biomedical Advanced Research and Development Authority (BARDA) Exercises Option with Pfenex Inc. To Extend Contract for the Development of a Recombinant Protective Antigen (rPA) Based Anthrax Vaccine
10. ResearchMoz: The World Anesthesia Drug Market (General, Local, Adjunctive) - Market Research Report
11. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 2014 Research and Markets has ... by Equipment, by Reagent, by Application - Global Forecast ... http://photos.prnewswire.com/prnh/20130307/600769 Biopharmaceuticals are ... one of the most important and widely used techniques ... segment of the cell culture market in 2013. Growth ...
(Date:7/22/2014)... 22, 2014  Decision Resources Group finds that the market ... will remain relatively stagnant at a value of around ... percutaneous coronary intervention (PCI) volumes are growing faster in ... as the United States and ... by the increase in penetration of PCI procedures relative to ...
(Date:7/22/2014)... , July 22, 2014 Legislation backed ... Access to Local Pharmacies Act of 2014") championing ... D would undermine the availability of lower cost ... $21 billion over the next 10 years, according ... by the Pharmaceutical Care Management Association (PCMA). ...
Breaking Medicine Technology:Global Cell Culture (Bioreactor, Incubator, Centrifuge) Market - Forecast to 2018 2Global Cell Culture (Bioreactor, Incubator, Centrifuge) Market - Forecast to 2018 3The Canadian Interventional Cardiology Device Market Will Remain Relatively Stagnant Through 2022 at Around $80 Million 2The Canadian Interventional Cardiology Device Market Will Remain Relatively Stagnant Through 2022 at Around $80 Million 3New Study: H.R. 4577 to Cost $21 Billion over 10 Years 2New Study: H.R. 4577 to Cost $21 Billion over 10 Years 3
... Mylan Inc. (Nasdaq: MYL ) today ... final approval from the U.S. Food and Drug Administration ... Valacyclovir Hydrochloride Tablets, 500 mg (base) and 1000 mg ... for the herpes virus infection. The product is being ...
... National Anesthesia Services, Inc. celebrates its 21st anniversary as one of ... a locum tenens and permanent basis in hospitals, surgery centers and medical ... , , ... when we first began," said president and owner Stephen Read . ...
Cached Medicine Technology:Mylan Receives Approval for Generic Version of Valtrex® 2National Anesthesia Services, Inc. Celebrates 21 Years of Dynamic Growth and Achievement 2
(Date:7/22/2014)... on cholesterol treatment and cardiovascular risk assessment state that ... from atherosclerotic cardiovascular disease or of having a heart ... risk profile (based on age, smoking history, and cholesterol ... for when and how aggressively to treat high cholesterol ... Men,s Health , a peer-reviewed publication from Mary Ann ...
(Date:7/22/2014)... (LALCA 2014) will be held August 21 23, ... the leading cause of death not only in Latin ... previous conferences in Chile, Mexico, Argentina and Brazil, international ... in the treatment and prevention of lung cancer and ... With tobacco being the leading cause of morbi-mortality worldwide ...
(Date:7/22/2014)... The Beryl Institute announces its fifth annual ... Program. These offerings reinforce the Institute’s commitment to support ... and the need for rigorous research to understand and ... programs are intended to encourage and support research ... on the patient experience before, during and after care ...
(Date:7/22/2014)... Ticket Down is a reliable source for cheap Manchester ... MD. There has never been a better time in the ... success of the American national soccer team at the 2014 World ... that fans of the world’s sport will be able to feed ... Champions Cup. The tournament will kick off on July 24 and ...
(Date:7/22/2014)... New York, NY (PRWEB) July 22, 2014 ... Risperdal lawsuits ( http://www.risperdallawsuitcenter.com/ ) in ... his decision to deny punitive damages in cases ... (male breast growth), Bernstein Liebhard LLP reports. In ... New also denied a plaintiffs’ request to certify ...
Breaking Medicine News(10 mins):Health News:The Beryl Institute Opens Applications for 2014 Patient Experience Grant and Scholar Programs 2Health News:The Beryl Institute Opens Applications for 2014 Patient Experience Grant and Scholar Programs 3Health News:Manchester United vs. Inter Milan Tickets Fedex Field Landover: Ticket Down Slashes Ticket Prices for Inter Milan ManU International Champions Cup Match in Washington, DC 2Health News:Manchester United vs. Inter Milan Tickets Fedex Field Landover: Ticket Down Slashes Ticket Prices for Inter Milan ManU International Champions Cup Match in Washington, DC 3Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 4
... taking the contraceptive pill may find themselves less responsive to ... The study, published in the journal Human Reproduction, measured the ... - while taking and not taking the Pill. ... experienced rises and falls in their ability to sense smells, ...
... vocal cords improves voice problems in Parkinson's disease. One of ... voice quality experienced by some patients. This problem is known ... abnormalities in the area of the voice box or larynx.// ... may be hard to understand what they are saying. You ...
... might explain common digestive symptoms like gas, pain and ... the link between fructose intolerance and the symptoms of ... abdominal discomfort, bloating and changes in bowel habit. Fructose ... honey. Some people can't digest it, but the condition ...
... past evidence that hormone replacement might lower stroke risk ... does not protect women from recurrent strokes and may ... evidence that hormone replacement therapy does not have the ... doctors have long thought hormone replacement therapy might help ...
... cheese and whole milk may be at increased risk ... The rates of two types of cancer--gastric cardia and ... 30 years. To investigate potential links between these and ... dietary factors, Dr. Susan T. Mayne from Yale University ...
... who undergo surgery for breast cancer will experience ... surgery, according to new research. Dr. Erica S. ... colleagues reported the findings at the American Public ... researchers asked 266 women who had undergone breast ...
Cached Medicine News:
... Mammography has been FDA approved, and represents ... It is the first and only mammography ... - the highest available. SenoScan's larger field ... breast support is more comfortable and helps ...
... The P3000 heralds a new concept in pupillometry, ... infrared optical system developed for the P2000. ... in which we have paid particular attention to ... Our new system is extremely flexible, allowing you ...
... the most useful features is the PupilFit ... mathematical analysis of the pupil images, producing ... instantaneously. The fitted circle is shown as ... proof that the measurement ismeaningful, and not ...
... An easy-to-operate, semi-automatic urine analyzer that ensures ... your lab efficiency by reducing "hands on" ... makes it an ideal fit for work ... Criterion II Analyzer is designed for continuous ...
Medicine Products: